Who are FF/UMEC/VI (100/31.25/25) mcg's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fluticasone furoate/umeclidinium/vilanterol, FF/UMEC/VI (200/31.25/25) mcg.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ff-umec-vi-100-31-25-25-mcg.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

FF/UMEC/VI (100/31.25/25) mcg — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FF/UMEC/VI (100/31.25/25) mcg (FF/UMEC/VI (100/31.25/25) mcg) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Triple-combination inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta-2 agonist. Area: Respiratory/Pulmonology.

phase 3 Triple-combination inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta-2 agonist Glucocorticoid receptor, M3 muscarinic receptor, beta-2 adrenergic receptor Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

FF/UMEC/VI (100/31.25/25) mcg (FF/UMEC/VI (100/31.25/25) mcg) — GlaxoSmithKline. FF/UMEC/VI is a triple-combination inhaled therapy that combines a long-acting beta-2 agonist, a long-acting muscarinic antagonist, and an inhaled corticosteroid to reduce airway inflammation and improve bronchodilation in chronic obstructive pulmonary disease.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
FF/UMEC/VI (100/31.25/25) mcg TARGET	FF/UMEC/VI (100/31.25/25) mcg	GlaxoSmithKline	phase 3	Triple-combination inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta-2 agonist	Glucocorticoid receptor, M3 muscarinic receptor, beta-2 adrenergic receptor
Fluticasone furoate/umeclidinium/vilanterol	Fluticasone furoate/umeclidinium/vilanterol	GlaxoSmithKline	marketed	Inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta-2 agonist combination	Glucocorticoid receptor, M3 muscarinic receptor, beta-2 adrenergic receptor
FF/UMEC/VI (200/31.25/25) mcg	FF/UMEC/VI (200/31.25/25) mcg	GlaxoSmithKline	phase 3	Triple combination inhaler (ICS/LAMA/LABA)	Glucocorticoid receptor, M3 muscarinic receptor, beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Triple-combination inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta-2 agonist class)

GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FF/UMEC/VI (100/31.25/25) mcg — Competitive Intelligence Brief. https://druglandscape.com/ci/ff-umec-vi-100-31-25-25-mcg. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab